Contact
searchSearch
HMP Global
Login

News

News
Fewer Cycles of Platinum-Based Chemotherapy Potentially Preserves Outcomes and Tolerability in Advanced Urothelial Carcinoma
10/17/2025
Stephanie Holland
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS...
10/17/2025
Oncology
News
Fewer Cycles of Platinum-Based Chemotherapy Potentially Preserves Outcomes and Tolerability in Advanced Urothelial Carcinoma
10/17/2025
Stephanie Holland
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS...
10/17/2025
Oncology
Conference Coverage
Cemiplimab Added to Chemotherapy Shows Promise for Advanced Penile Carcinoma
02/13/2025
Allison Casey
According to a phase 2 study, cemiplimab plus standard-of-care chemotherapy demonstrated efficacy and safety among patients with locally advanced or metastatic penile carcinoma.
According to a phase 2 study, cemiplimab plus standard-of-care chemotherapy demonstrated efficacy and safety among patients with locally advanced or metastatic penile carcinoma.
According to a phase 2 study,...
02/13/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
Stephanie Holland
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
News
Sacituzumab Govitecan Advised as Potential Combination Therapy With Pembrolizumab in mUC
02/23/2022
John Otrompke, BA, JD
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be studied further as a potential addition to standard-of-care CPI treatment as a combo regimen for metastatic urothelial cancer following platinum-based regimens.
Sacituzumab govitecan willl be...
02/23/2022
Oncology
News
FDA Approves Sacituzumab Govitecan for Advanced Urothelial Cancer
04/13/2021
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated approval to sacituzumab govitecan for the treatment of certain adults with locally advanced or metastatic urothelial cancer.
The FDA has granted accelerated...
04/13/2021
Oncology
News
Study Predicts Risk of Recurrence, Progression for Patients With NMIBC
02/19/2021
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based cohort study of patients with NMIBC suggest that 1- and 5-year high-risk recurrences and progression increase with higher tumor classification and grade at diagnosis.
Data from a community-based...
02/19/2021
Oncology
News
Salvage Ipilimumab Plus Nivolumab Active in Metastatic RCC
07/29/2020
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab yielded anti-tumor activity with acceptable toxicity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Ipilimumab plus nivolumab...
07/29/2020
Oncology
News
Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer
07/27/2020
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.
Pembrolizumab was active in...
07/27/2020
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use